이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pulse Biosciences 관리

관리 기준 확인 2/4

Pulse Biosciences' CEO는 Burke Barrett, May2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 114.01K 가치에 해당하는 회사 주식의 0.018% 직접 소유합니다. 114.01K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 6.6 년입니다.

주요 정보

Burke Barrett

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.02%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

CEO

Burke Barrett (60 yo)

less than a year

테뉴어

Mr. Burke T. Barrett is President & CEO of Pulse Biosciences, Inc. from May 14, 2024 and also serves as its Director since May 2024. Mr. Barrett served as President, Secretary and Director of CardioFocus,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Duggan	Executive Chairman	6.7yrs	US$257.41k	61.21% $ 451.6m
Darrin Uecker	CTO & Director	1.8yrs	US$5.39m	0.25% $ 1.8m
Mitchell Levinson	Chief Strategy Officer	2.9yrs	US$1.69m	0.16% $ 1.2m
Kevin Danahy	Chief Commercial Officer	less than a year	US$5.86m	0.059% $ 432.4k
Burke Barrett	President	less than a year	데이터 없음	0.016% $ 120.5k
Edison Manuel	Vice President of Operations	7.3yrs	데이터 없음	데이터 없음
Richard Nuccitelli	Chief Science Officer	9.7yrs	데이터 없음	데이터 없음
Kenneth B. Stratton	General Counsel & Corporate Secretary	3.2yrs	데이터 없음	데이터 없음
Patty Perla	Vice President of Human Resources	4.5yrs	데이터 없음	데이터 없음
David Danitz	Senior Vice President of Engineering	2.8yrs	데이터 없음	데이터 없음
Gansevoort Dunnington	Chief Medical Officer	1.2yrs	데이터 없음	데이터 없음
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: PLSE 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Duggan	Executive Chairman	6.7yrs	US$257.41k	61.21% $ 451.6m
Darrin Uecker	CTO & Director	8.8yrs	US$5.39m	0.25% $ 1.8m
Burke Barrett	President	less than a year	데이터 없음	0.016% $ 120.5k
Richard van den Broek	Independent Director	3.9yrs	US$208.89k	0% $ 0
Mahkam Zanganeh	Independent Director	7.4yrs	US$173.00k	1.23% $ 9.1m
Manmeet Soni	Lead Independent Director	6.7yrs	US$180.07k	0% $ 0

6.7yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: PLSE 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

Pulse Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Recent updates

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated

Price target decreased to US$37.95

Independent Chairman of the Board recently bought US$50m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences gets Health Canada approval for CellFX System

Consensus forecasts updated

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?

Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?

Pulse Biosciences Announces First CellFX Procedures